---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000132"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:28.049689+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone

## Summary
- FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.
- FDA approval triggers $30M milestone payment from Blackstone to Autolus.
- Cash and equivalents totaled $657.1M at Sep 30, 2024, up from $239.6M at Dec 31, 2023.
- Net loss of $82.1M for Q3 2024 vs $45.8M in Q3 2023; diluted EPS -$0.31.
- Matthias Will M.D. appointed Chief Development Officer effective Sep 30, 2024.

## SEC filing metadata
- accession: 0001730463-24-000132
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/0001730463-24-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autl-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000132
- JSON: https://secwatch.observer/filing/0001730463-24-000132.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.